CELLSEARCH® Circulating Tumor Cell Test in metastatic colorectal cancer (mCRC)—clinical trials and real-world case studies

Pivotal Clinical Trial—Circulating tumor cells (CTCs) as a predictive marker of tumor response, progression-free survival, and overall survival (OS) in patients with mCRC1,2

Trial design

CTCs were monitored in 430 mCRC patients at baseline and after starting 1st, 2nd, or 3rd line therapy.1

Results

OS in mCRC Patients With CTCs <3 or ≥3 at Baseline
 OS According to CTC Status Throughout Follow-up—Prognosis Was More Favorable in Patients With <3 CTCs
OS in mCRC Patients With Nonprogressive Disease (NPD) Versus Progressive Disease (PD) Based on Imaging Studies—CTCs Were a More Accurate Indicator of Prognosis
References: 
  1. Cohen SJ, Punt CJA, Iannotti N, et al. J Clin Oncol. 2008;26(19):3213-3221.
  2. CELLSEARCH® Circulating Tumor Cell Kit (Epithelial) Instructions for Use. Janssen Diagnostics, LLC.